Paolo Lanzetta

62PUBLICATIONS
105CO-AUTHORS
Optical technologyAutoimmunityEpigenetics (incl. genome methylation and epigenomics)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular imaging (incl. electron microscopy and neutron diffraction)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (62)

|Jul 11, 2026
SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema.

|Jul 06, 2026
Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication.

|Jun 25, 2026
Iridology: Biological plausibility, clinical evidence, and implications for ophthalmic practice : A position paper of the Associazione Pazienti Malattie Oculari (APMO).

|Jun 21, 2026
Comment to: Hashiya N, Maruko I, Maruko R et al. Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol (2026) 264:1611-1617. doi:10.1007/s00417-026-07117-3.

|Jun 18, 2026
Enhanced S-cone syndrome in a family: first long-term (12-year) follow-up and literature review.

|Jun 13, 2026
Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON.

Pageof 11

Frequent Collaborators

17 joint publications

Daniele Veritti

14 joint publications

Valentina Sarao

8 joint publications

Francesco Bandello

6 joint publications

Carla Danese